The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data.

Article Details

Citation
Copy to clipboard

Out HJ, Mannaerts BM

The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data.

Hum Fertil (Camb). 2002 Feb;5(1):G5-10; discussion G10-2, G41-8. doi: 10.1080/1464727992000199771.

PubMed ID
11939160 [ View in PubMed
]
Abstract

The gonadotrophin-releasing hormone antagonist ganirelix has recently become available to clinicians. Its indication, prevention of premature luteinizing hormone surges in assisted reproduction programmes, has been investigated extensively in numerous studies. This article summarizes the major results from pharmacokinetics studies, a double-blind dose-finding trial and three large-scale phase III randomized clinical trials, comparing ganirelix and the most commonly used gonadotrophin-releasing hormone agonists, buserelin,leuprolide and triptorelin, in a long protocol. It is concluded that controlled ovarian hyperstimulation with ganirelix offers significant advantages in terms of convenience of treatment as reflected in a considerably reduced treatment period.Safety and tolerance as well as overall clinical outcome are good.

DrugBank Data that Cites this Article

Drugs